Search research articles
Contact Us
Filters
Showing results (1-10 of 39) with videos related to
Page
of 4
Sort By:
Current Medical Research and Opinion
|
March 29, 2020
The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis
Imtiaz A Samjoo, Evelyn Worthington, Anja Haltner, et al.
Journal of Neurology
|
September 20, 2005
Genomics and proteomics: role in the management of multiple sclerosis
Ludwig Kappos, Lutz Achtnichts, Frank Dahlke, et al.
Current Medical Research and Opinion
|
March 30, 2020
Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis
Imtiaz A Samjoo, Evelyn Worthington, Anja Haltner, et al.
Neurology
|
October 3, 2022
Author Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials
David Leppert, Harald Kropshofer, Dieter Häring, et al.
Neurology
|
April 21, 2025
Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials
Ludwig Kappos, Sean Yiu, Frank Dahlke, et al.
Current Medical Research and Opinion
|
August 13, 2021
Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses
Imtiaz A Samjoo, Evelyn Worthington, Anja Haltner, et al.
JMIR Medical Informatics
|
April 15, 2020
A Novel, Integrative Approach for Evaluating Progression in Multiple Sclerosis: Development of a Scoring Algorithm
Chloe Tolley, Daniela Piani-Meier, Sarah Bentley, et al.
Neurology
|
April 5, 2022
Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials
David Leppert, Harald Kropshofer, Dieter A Häring, et al.
European Journal of Neurology
|
August 25, 2021
Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing-remitting multiple sclerosis
Dawn W Langdon, Davorka Tomic, Iris-Katharina Penner, et al.
Neurology
|
February 10, 2019
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
Jens Kuhle, Harald Kropshofer, Dieter A Haering, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 39) with videos related to
Sort By:
Page
of 4
Current Medical Research and Opinion
|
March 29, 2020
The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis
Imtiaz A Samjoo, Evelyn Worthington, Anja Haltner, et al.
Journal of Neurology
|
September 20, 2005
Genomics and proteomics: role in the management of multiple sclerosis
Ludwig Kappos, Lutz Achtnichts, Frank Dahlke, et al.
Current Medical Research and Opinion
|
March 30, 2020
Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis
Imtiaz A Samjoo, Evelyn Worthington, Anja Haltner, et al.
Neurology
|
October 3, 2022
Author Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials
David Leppert, Harald Kropshofer, Dieter Häring, et al.
Neurology
|
April 21, 2025
Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials
Ludwig Kappos, Sean Yiu, Frank Dahlke, et al.
Current Medical Research and Opinion
|
August 13, 2021
Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses
Imtiaz A Samjoo, Evelyn Worthington, Anja Haltner, et al.
JMIR Medical Informatics
|
April 15, 2020
A Novel, Integrative Approach for Evaluating Progression in Multiple Sclerosis: Development of a Scoring Algorithm
Chloe Tolley, Daniela Piani-Meier, Sarah Bentley, et al.
Neurology
|
April 5, 2022
Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials
David Leppert, Harald Kropshofer, Dieter A Häring, et al.
European Journal of Neurology
|
August 25, 2021
Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing-remitting multiple sclerosis
Dawn W Langdon, Davorka Tomic, Iris-Katharina Penner, et al.
Neurology
|
February 10, 2019
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
Jens Kuhle, Harald Kropshofer, Dieter A Haering, et al.
Page
of 4